Loading…
← CockpitCompetitor Analysis › 603456.SS Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A603456.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese CDMO and API manufacturer providing contract development/manufacturing services to global and domestic pharma companies.

≈ A Chinese WuXi STA/Lonza (CDMO)Momentum leader 86
Mkt cap
$2.03B
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$44.2M
20-day average traded
Fwd P/E
16.9×
forward earnings
ROIC−WACC
+2.5 pp
WACC 7.6%
Hurdle
-14 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥15.48
1D-3.4%
1W-6.9%
1M-7.9%
3M-15.2%
6M+19.2%
YTD-13.5%
1Y-21.6%
ATR %4.6%
52w lowhigh30.4% off high

What Zhejiang Jiuzhou Pharmaceutical does

Chinese CDMO and API manufacturer providing contract development/manufacturing services to global and domestic pharma companies.

Earns from multi-year contract manufacturing for global drugmakers, making intermediates and the active ingredient for products still in development, so revenue scales as those drugs move to launch; routine API sales of established products are a separate line. Audits by the US and European regulators underpin customers' trust.

In one line: A Chinese WuXi STA/Lonza (CDMO).

Products and services

  • CDMO contract manufacturing
  • Active pharmaceutical ingredients (APIs)
  • Formulation manufacturing

Customers

  • Global pharma companies (CDMO clients)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • CDMO + API manufacturing

What could go right

  • Global pharma CDMO outsourcing growth

What could go wrong

  • Customer concentration
  • CDMO capacity/price competition

Moat: narrow (scale, regulatory licence, customer qualification). FDA/EU-audited manufacturing capacity and long-standing CDMO relationships with global pharma.

Headquarters: Taizhou, Zhejiang, China · Employees: 4,791

Named competitors

Zhejiang Jiuzhou Pharmaceutical at a glance

Size Zhejiang Jiuzhou Pharmaceutical (603456.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.03B, the 1154th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.48 on 18 Nov 2026.

Performance Over six months the shares gained 19.2%, against -5.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 1.3% over the last twelve months (peer median +10.7%); the operating margin is 14.1% (peer median 22.2%).

Valuation It trades at 16.9× forward earnings against a peer median of 18.1× (9th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.5 points above its cost of capital (7.6% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026603456.SS 121Peer median 93
Six months, rebased to 100: Zhejiang Jiuzhou Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Jiuzhou Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥5.28BCN¥5.47BCN¥5.13BCN¥5.50BCN¥5.43B
Revenue growth—+7%-7%+1%—
Gross profitCN¥2.13BCN¥1.87BCN¥1.60BCN¥1.94BCN¥1.77B
EBITDAn/aCN¥1.48BCN¥1.11BCN¥1.47BCN¥1.38B
Net incomeCN¥599MCN¥730MCN¥606MCN¥1.03BCN¥921M
Free cash flowCN¥842MCN¥1.17BCN¥105MCN¥431MCN¥517M
Capital expenditureCN¥563MCN¥660MCN¥889MCN¥929MCN¥714M
Total debtCN¥240MCN¥195MCN¥705MCN¥728MCN¥820M

Quarterly statements and history in the cockpit →

Zhejiang Jiuzhou Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%6037073004366002850094209969ERISH02214450BHVNONESOURCEHRMY60020145400512SHILPAMEDALIVUSPFIZER300009600211600267603456.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Jiuzhou Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%20×40×60×6037076002859969ERISH02214450ONESOURCEHRMY6002014540SHILPAMEDALIVUS300009600211603456.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Jiuzhou Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%6037076002859969ERIS214450600267603456.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Jiuzhou Pharmaceutical is the large dot.

Zhejiang Jiuzhou Pharmaceutical competitors and peer comparison

Head to head with its named competitors (603456.SS vs 2359.HK vs 000739.SZ vs 002821.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang Jiuzhou Pharmaceutical 603456.SS$2.03B+19%-1%14%16.9×1.7%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Apeloa Pharmaceutical 000739.SZ$3.37B+17%-16%10%22.9×4.7%
Asymchem Laboratories (Tianjin) 002821.SZ$7.27B+20%+18%17%37.4×n/a
Porton Pharma Solutions 300363.SZ$1.66B+37%+6%-2%n/a2.1%
Zhejiang Huahai Pharmaceutical 600521.SS$3.61B0%+10%12%20.1×6.4%
Zhejiang Medicine 600216.SS$1.51B-26%-6%7%11.5×-7.8%

How Zhejiang Jiuzhou Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Jiuzhou Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603456.SSPeer medianRank in peer set
1-month return-7.9%+2.7%5th lowest of 21
6-month return+19.2%-5.5%4th highest of 21
Distance from 52-week high-30.4%-26.0%8th lowest of 21
Revenue growth (TTM)-1.3%+10.7%4th lowest of 20
Operating margin14.1%22.2%7th lowest of 20
Forward P/E16.9×18.1×9th cheapest of 18
Growth the price implies (Req g, 7 yrs)1.7%2.2%8th least demanding of 15
Growth delivered (Del g)+15.7%+12.3%6th highest of 15
Hurdle (Req g minus delivered)-14.0 pp-10.3 pp6th least demanding of 15
ROIC minus cost of capital+2.5 pp+1.6 pp10th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%

Questions

Who are Zhejiang Jiuzhou Pharmaceutical's main competitors?
Named competitors: WuXi AppTec (2359.HK), Apeloa Pharmaceutical (000739.SZ), Asymchem Laboratories (002821.SZ), Porton Pharma Solutions (300363.SZ), Zhejiang Huahai Pharmaceutical (600521.SS), Zhejiang Medicine (600216.SS). The cockpit's measured peer set (industry) also includes Nanjing King-friend Biochemical Pharmaceutical (603707.SS), Fujian Cosunter Pharmaceutical (300436.SZ), Henan Lingrui Pharmaceutial (600285.SS), Hanall Biopharma (009420.KS), InnoCare Pharma (9969.HK), Eris Lifesciences (ERIS.NS).
Is Zhejiang Jiuzhou Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 16.9× against a peer median of 18.1×, 9th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Zhejiang Jiuzhou Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +19.2% against -5.5% for the median peer; over one year -21.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.